Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report.
Acute severe ulcerative colitis
Case report
Inflammatory bowel disease
Infliximab
Toxic megacolon
Ulcerative colitis
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
06 May 2021
06 May 2021
Historique:
received:
09
01
2021
revised:
04
02
2021
accepted:
09
03
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
ppublish
Résumé
Acute severe ulcerative colitis (ASUC) is a complication of ulcerative colitis associated with high levels of circulating tumor necrosis factor alpha, due to the intense inflammation and faster stool clearance of anti-tumor necrosis factor drugs. Dose-intensified infliximab treatment can be beneficial and is associated with lower rates of colectomy. The aim of the study was to present a case of a patient with ASUC and megacolon, treated with hydrocortisone and accelerated scheme of infliximab that was monitored by drug trough level. A 22-year-old female patient diagnosed with ulcerative colitis, presented with diarrhea, rectal bleeding, abdominal pain, vomiting, and distended abdomen. During investigation, a positive toxin for Infliximab accelerated infusions can be beneficial in ASUC unresponsive to the treatment with intravenous corticosteroids. Longitudinal studies are necessary to define the best therapeutic drug monitoring and treatment regimen for these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Acute severe ulcerative colitis (ASUC) is a complication of ulcerative colitis associated with high levels of circulating tumor necrosis factor alpha, due to the intense inflammation and faster stool clearance of anti-tumor necrosis factor drugs. Dose-intensified infliximab treatment can be beneficial and is associated with lower rates of colectomy. The aim of the study was to present a case of a patient with ASUC and megacolon, treated with hydrocortisone and accelerated scheme of infliximab that was monitored by drug trough level.
CASE SUMMARY
METHODS
A 22-year-old female patient diagnosed with ulcerative colitis, presented with diarrhea, rectal bleeding, abdominal pain, vomiting, and distended abdomen. During investigation, a positive toxin for
CONCLUSION
CONCLUSIONS
Infliximab accelerated infusions can be beneficial in ASUC unresponsive to the treatment with intravenous corticosteroids. Longitudinal studies are necessary to define the best therapeutic drug monitoring and treatment regimen for these patients.
Identifiants
pubmed: 33969111
doi: 10.12998/wjcc.v9.i13.3219
pmc: PMC8080733
doi:
Types de publication
Case Reports
Langues
eng
Pagination
3219-3226Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors state that they have no conflicts of interest regarding this case report.
Références
Dig Dis Sci. 2019 Feb;64(2):518-523
pubmed: 30446928
J Crohns Colitis. 2017 Jun 1;11(6):697-705
pubmed: 27838610
Ther Adv Chronic Dis. 2018 Feb;9(2):65-72
pubmed: 29387331
Aliment Pharmacol Ther. 2017 Mar;45(5):617-630
pubmed: 28074618
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Clin Gastroenterol Hepatol. 2015 Feb;13(2):330-335.e1
pubmed: 25086187
J Crohns Colitis. 2020 Jul 30;14(7):1026-1028
pubmed: 32020189
Aliment Pharmacol Ther. 2019 Sep;50(6):675-683
pubmed: 31456297
Aliment Pharmacol Ther. 2015 Jun;41(11):1094-103
pubmed: 25809869
J Crohns Colitis. 2016 Sep;10(9):1015-23
pubmed: 27022161
Aliment Pharmacol Ther. 2002 Jul;16 Suppl 4:7-12
pubmed: 12047253
Gastroenterology. 2015 Aug;149(2):350-5.e2
pubmed: 25917786
Dig Dis Sci. 2019 May;64(5):1119-1128
pubmed: 30535888